Transitional cell carcinoma

This trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…

This trial tests whether giving a combination of two chemotherapy drugs, gemcitabine and cisplatin, before surgery can shrink high-grade tumors in the upper urinary tract, a type of kidney cancer. Participants receive four cycles of the drugs over about 12 weeks, followed by surg…

This trial tests whether combining two DNA-based immunotherapies with the drug atezolizumab can help people with advanced urothelial carcinoma, a type of cancer of the bladder and urinary tract. The DNA therapies are injected into muscle and followed by a brief electric pulse to …

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This early-stage trial tests an experimental antibody called JS004, which targets a protein on immune cells called BTLA, to see if it can help the immune system fight advanced solid tumors like melanoma, kidney cancer, and bladder cancer. The study includes JS004 alone or combine…

This phase 3 trial tested whether adding bevacizumab (Avastin) to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced urinary tract cancer live longer. 506 patients with cancer that had spread or could not be removed by surgery took part. The study compar…

This early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…

This large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…

This study tested a drug called sacituzumab govitecan given before bladder removal surgery in 44 people with muscle-invasive bladder cancer who could not take or refused standard cisplatin chemotherapy. The goal was to see if the drug could completely eliminate the tumor by the t…

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…

This phase 2 trial tested a combination of two chemotherapy drugs, cabazitaxel and cisplatin, given before surgery to remove the bladder in 28 patients with invasive bladder cancer. The goal was to see if the drugs could shrink the tumor enough to improve outcomes. The study also…

This study tested whether adding lenvatinib to pembrolizumab (immunotherapy) helps people with advanced bladder cancer live longer or keep their cancer from growing. It included 505 people whose cancer had spread and who could not take the chemotherapy drug cisplatin. The trial w…

This early-phase study tested whether genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T) are safe for people with advanced urothelial cancer, melanoma, or head and neck cancer. Ten participants received their own engineered immune cells after chemotherapy. The main goal was to check fo…

This completed phase 2 trial tested a combination of cryoablation (freezing tumors with a needle) and immunotherapy drugs (pembrolizumab or avelumab) in 9 people with metastatic bladder cancer. The goal was to see if this approach could shrink tumors that were not frozen. The stu…

This study tested a combination of two drugs (toripalimab and gemcitabine) given before surgery to 50 people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. The goal was to see how many patients had their tumors shrink or disappear. T…

This early-phase study tested a combination of two drugs—avelumab (an immunotherapy) and docetaxel (a chemotherapy)—in 21 people with advanced bladder cancer that had stopped responding to standard platinum chemotherapy. The main goals were to check safety and see if the combinat…

This phase 2 trial tested pemigatinib, a daily pill that blocks certain growth signals, in 30 people with recurrent low- or intermediate-risk non-muscle invasive bladder cancer. Participants took the drug for 4-6 weeks before their standard surgery to remove bladder tumors. The m…

This early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…

This study collects blood, tissue, and urine from about 589 people with different types of kidney or urinary tract tumors, plus healthy volunteers. Researchers are looking for special DNA markers (methylated DNA) that could help detect these cancers earlier and more accurately. T…

This pilot study tested whether a new radioactive tracer called 18F-fluciclovine, used with a PET/CT scan, can better determine the extent of muscle invasive bladder cancer before surgery. Sixteen participants with bladder cancer received the tracer and scan before their planned …

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to…

This study looked at whether a urine test called Cxbladder can accurately detect bladder cancer in 682 people who had blood in their urine. The test's results were compared to the standard method, a camera exam of the bladder (cystoscopy). The goal was to see if the urine test co…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study reviews medical records of 360 Japanese patients with advanced bladder cancer who received avelumab as a maintenance treatment after initial chemotherapy. The goal is to understand patient characteristics, treatment patterns, and outcomes like survival and tumor respon…

This study analyzes data from 748 patients who had their bladder removed due to bladder cancer. The goal is to find factors that can predict whether cancer has spread to the ureter, the tube that carries urine from the kidney to the bladder. By identifying these factors, doctors …

This study looks at how adults with advanced bladder cancer are treated in everyday medical practice, not in a controlled trial. Researchers will analyze data from cancer clinics to see how long patients go without their disease worsening after starting their first treatment. The…

This completed study tracked 596 patients in France with advanced bladder cancer who received avelumab as maintenance therapy after initial chemotherapy. Researchers observed how long patients survived and how the drug performed in everyday medical practice, rather than in a cont…

This completed pilot study looked at whether the proteins produced by gut bacteria differ between bladder cancer patients who respond to immunotherapy and those who do not. Researchers collected stool and blood samples from 40 patients with advanced bladder cancer. The goal was t…

This completed study tested a 3-D cell culture method to isolate and grow circulating tumor cells (CTCs) from blood samples of 160 people with and without cancer. The goal was to see if this method could reliably expand CTC numbers for research. If it works, it could improve how …